Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. These forward-looking statements relate to a variety of matters, including, without limitation, the timing, size, success and intended use of net proceeds of the proposed offering as well as statements that relate to Spectrum’s business and its future, including Spectrum’s ability to advance development of its late-stage pipeline assets and such assets’ ability to serve areas of unmet need; the future potential of Spectrum’s existing drug pipeline; and other statements containing the words "anticipate,” "believe,” "continue,” "contemplate,” "could,” "estimate,” "expect,” "intend,” "may,” "plan,” "potential,” "predict,” "project,” "should,” "target,” "will,” "would,” and similar expressions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Commerce Policy |
// ]]>
A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Acute Lymphoblastic Leukemia Therapeutics Market 2020 Status and Outlook – Erytech Pharma, Spectrum Pharmaceuticals, Pfizer, Sigma-Tau, … In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments. Copyright © 2020 MarketWatch, Inc. All rights reserved. ©Spectrum Chemical
Top LeadingCompanies of Global Acute Lymphoblastic Leukemia Therapeutics Market are Erytech Pharma, Spectrum Pharmaceuticals, Pfizer, Sigma-Tau, Takeda, Genzyme Corporatio, GSK, Amgen(NASDAQ: AMGN), EUSA Pharma, ARIAD Pharmaceuticals, Talon Therapeutics, Enzon, Inc., Nova Laboratories, Bristol-Myers Squibb(NYSE: BMY), Silvergate Pharmaceuticals and others. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Spectrum Pharmacy Products is a division of Spectrum Laboratory Products, Inc., a company founded in 1971 as a fine chemical manufacturer. By using this site you agree to the The company planned to focus on developing poziotinib and its second key product candidate, Rolontis, a treatment for chemotherapy-induced neutropenia, an abnormally low white blood cell count that is a side effect of cancer treatments. All rights reserved. 524804, Spectrum expects to use the net proceeds from this offering for general corporate purposes, including, without limitation, the continued development of its pipeline assets, sales and marketing activities, pre-launch activities associated with ROLONTIS and potential business development initiatives. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. Notice Regarding Forward-Looking Statements.